During the past decade, Cannock Chase Hospital conducted 2 clinical trials. In the 10-year time frame, 2 clinical trials started and 2 clinical trials were completed, i.e. on average, 100% percent of trials that started reached the finish line to date. In the past 5 years, 2 clinical trials started and 0 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

According to Clinical.Site data, the most researched conditions in "Cannock Chase Hospital" are "Psoriatic Arthritis" (2 trials), "Arthritis, Psoriatic" (1 trials) and "Lupus Erythematosus, Systemic" (1 trials). Many other conditions were trialed in "Cannock Chase Hospital" in a lesser frequency.

Most popular intervention types in "Cannock Chase Hospital" are "Drug" (4 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (3 trials), "Apremilast 20mg" (2 trials), "Apremilast 30mg" (2 trials), "BIIB059 (litifilimab)" (1 trials) and "Guselkumab 100 mg" (1 trials). Other intervention names were less common.

The vast majority of trials in "Cannock Chase Hospital" are 4 trials for "All" genders.

Currently, there are NaN active trials in "Cannock Chase Hospital". undefined are not yet recruiting, 1 are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 3 completed trials in Cannock Chase Hospital, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Cannock Chase Hospital, 0 "Phase 1" clinical trials were conducted, 0 "Phase 2" clinical trials and 4 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".